KEROS THERAPEUTICS INC. - COMMON STOCK

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

14 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

05 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

28 фев 2024 16:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

29 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

09 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

03 янв 2024 21:29:25 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Proposed Public Offering of Common Stock

03 янв 2024 16:05:39 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

03 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

11 дек 2023 06:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

07 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results

06 ноя 2023 08:00:01 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition

02 ноя 2023 09:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

04 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

05 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

07 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

27 июл 2023 16:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference

12 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

09 июн 2023 06:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference

07 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

22 май 2023 09:00:00 Источник Nasdaq GlobeNewswire